<ul><li> Israeli AI drug discovery company Quris has raised USD 19 million—in addition to the initial USD 9 million seed funding raised in October 2021—in a seed funding round, totaling USD 28 million. The round was led by Welltech Ventures, with participation from iAngels, GlenRock Capital, and other investors.</ul>
The proceeds will be directed toward accelerating the research and development of novel therapeutics, growing its team, and entering into synergistic partnerships. The funds will also be used to test the first 100 or 1000 drugs to train the AI platform.
Having publicly launched its clinical-prediction AI platform last year, Quris plans to advance the first drug—to treat fragile X syndrome (FXS)—developed on the platform, toward clinical testing in 2022.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.